563
Participants
Start Date
January 26, 2016
Primary Completion Date
February 3, 2017
Study Completion Date
September 13, 2017
Fasinumab
Participants received fasinumab SC or IV, Q4W or Q8W.
placebo
Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
Birmingham
Chandler
Glendale
Mesa
Phoenix
Scottsdale
Tucson
Little Rock
Beverly Hills
Carlsbad
Lakewood
Long Beach
Sacramento
San Diego
Santa Rosa
Vista
Aurora
Colorado Springs
Littleton
Washington D.C.
Clearwater
Fort Myers
Leesburg
Miami
Orlando
Chicago
Evansville
Council Bluffs
Worcester
Edina
Kansas City
St Louis
Elkhorn
Henderson
Las Vegas
Jamaica
New York
Williamsville
Cary
High Point
Raleigh
Salisbury
Wilmington
Akron
Cincinnati
Columbus
Oklahoma City
Duncansville
Anderson
Greer
Bristol
Knoxville
Cypress
Dallas
Lubbock
Plano
San Antonio
Salt Lake City
London
Toronto
Prague
Rychnov nad Kněžnou
Aalborg
Ballerup Municipality
Tallinn
Budapest
Gyula
Szolnok
Bialystok
Lodz
Lublin
Rzeszów
Warsaw
Zgierz
Regeneron Pharmaceuticals
INDUSTRY